APA (7th ed.) Citation

A, B., B, L., VH, P., V, L., A, F., S, E., . . . K, E. (2023). Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up). Journal of the American Academy of Dermatology, 89(3), 478. https://doi.org/10.1016/j.jaad.2023.05.033

Chicago Style (17th ed.) Citation

A, Blauvelt, et al. "Efficacy and Safety of Switching from Dupilumab to Upadacitinib Versus Continuous Upadacitinib in Moderate-to-severe Atopic Dermatitis: Results from an Open-label Extension of the Phase 3, Randomized, Controlled Trial (Heads Up)." Journal of the American Academy of Dermatology 89, no. 3 (2023): 478. https://doi.org/10.1016/j.jaad.2023.05.033.

MLA (9th ed.) Citation

A, Blauvelt, et al. "Efficacy and Safety of Switching from Dupilumab to Upadacitinib Versus Continuous Upadacitinib in Moderate-to-severe Atopic Dermatitis: Results from an Open-label Extension of the Phase 3, Randomized, Controlled Trial (Heads Up)." Journal of the American Academy of Dermatology, vol. 89, no. 3, 2023, p. 478, https://doi.org/10.1016/j.jaad.2023.05.033.